Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 9.3 years: an updated integrated safety analysis
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Conference item |
Jezik: | English |
Izdano: |
Journal of Rheumatology
2022
|
Izvleček: |
---|